These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 21664851)

  • 21. S100A14 promotes progression and gemcitabine resistance in pancreatic cancer.
    Zhu H; Gao W; Li X; Yu L; Luo D; Liu Y; Yu X
    Pancreatology; 2021 Apr; 21(3):589-598. PubMed ID: 33579599
    [TBL] [Abstract][Full Text] [Related]  

  • 22. SPARC: A Potential Prognostic and Therapeutic Target in Pancreatic Cancer.
    Vaz J; Ansari D; Sasor A; Andersson R
    Pancreas; 2015 Oct; 44(7):1024-35. PubMed ID: 26335014
    [TBL] [Abstract][Full Text] [Related]  

  • 23. MicroRNA-21 in pancreatic cancer: correlation with clinical outcome and pharmacologic aspects underlying its role in the modulation of gemcitabine activity.
    Giovannetti E; Funel N; Peters GJ; Del Chiaro M; Erozenci LA; Vasile E; Leon LG; Pollina LE; Groen A; Falcone A; Danesi R; Campani D; Verheul HM; Boggi U
    Cancer Res; 2010 Jun; 70(11):4528-38. PubMed ID: 20460539
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Chemoradiation for ductal pancreatic carcinoma: principles of combining chemotherapy with radiation, definition of target volume and radiation dose.
    Wilkowski R; Thoma M; Weingandt H; Dühmke E; Heinemann V
    JOP; 2005 May; 6(3):216-30. PubMed ID: 15883472
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Molecular signatures of pancreatic cancer.
    Hong SM; Park JY; Hruban RH; Goggins M
    Arch Pathol Lab Med; 2011 Jun; 135(6):716-27. PubMed ID: 21631264
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cancer-associated fibroblasts promote progression and gemcitabine resistance via the SDF-1/SATB-1 pathway in pancreatic cancer.
    Wei L; Ye H; Li G; Lu Y; Zhou Q; Zheng S; Lin Q; Liu Y; Li Z; Chen R
    Cell Death Dis; 2018 Oct; 9(11):1065. PubMed ID: 30337520
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Gemcitabine: A Review of Chemoresistance in Pancreatic Cancer.
    Sarvepalli D; Rashid MU; Rahman AU; Ullah W; Hussain I; Hasan B; Jehanzeb S; Khan AK; Jain AG; Khetpal N; Ahmad S
    Crit Rev Oncog; 2019; 24(2):199-212. PubMed ID: 31679214
    [TBL] [Abstract][Full Text] [Related]  

  • 28. PANDA cyst-fluid analysis: eats, shoots and leaves?
    Anderson MA; Kwon RS; Scheiman JM
    Gastrointest Endosc; 2009 May; 69(6):1103-5. PubMed ID: 19410042
    [No Abstract]   [Full Text] [Related]  

  • 29. PIK3CA, KRAS, and BRAF mutations in intraductal papillary mucinous neoplasm/carcinoma (IPMN/C) of the pancreas.
    Schönleben F; Qiu W; Remotti HE; Hohenberger W; Su GH
    Langenbecks Arch Surg; 2008 May; 393(3):289-96. PubMed ID: 18343945
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Morphogenesis of pancreatic cancer: role of pancreatic intraepithelial neoplasia (PanINs).
    Koorstra JB; Feldmann G; Habbe N; Maitra A
    Langenbecks Arch Surg; 2008 Jul; 393(4):561-70. PubMed ID: 18283486
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Differential methylation landscape of pancreatic ductal adenocarcinoma and its precancerous lesions.
    Bararia A; Dey S; Gulati S; Ghatak S; Ghosh S; Banerjee S; Sikdar N
    Hepatobiliary Pancreat Dis Int; 2020 Jun; 19(3):205-217. PubMed ID: 32312637
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Preoperative chemoradiotherapy using gemcitabine for pancreatic ductal adenocarcinoma in patients with impaired renal function.
    Tomimaru Y; Eguchi H; Iwagami Y; Akita H; Noda T; Gotoh K; Kobayashi S; Nagano H; Mori M; Doki Y
    Cancer Chemother Pharmacol; 2020 Mar; 85(3):537-545. PubMed ID: 31834436
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Kras(G12D) and Smad4/Dpc4 haploinsufficiency cooperate to induce mucinous cystic neoplasms and invasive adenocarcinoma of the pancreas.
    Izeradjene K; Combs C; Best M; Gopinathan A; Wagner A; Grady WM; Deng CX; Hruban RH; Adsay NV; Tuveson DA; Hingorani SR
    Cancer Cell; 2007 Mar; 11(3):229-43. PubMed ID: 17349581
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pancreatic adenocarcinoma: ESMO-ESDO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
    Seufferlein T; Bachet JB; Van Cutsem E; Rougier P;
    Ann Oncol; 2012 Oct; 23 Suppl 7():vii33-40. PubMed ID: 22997452
    [No Abstract]   [Full Text] [Related]  

  • 35. BRD4 promotes pancreatic ductal adenocarcinoma cell proliferation and enhances gemcitabine resistance.
    Wang YH; Sui YN; Yan K; Wang LS; Wang F; Zhou JH
    Oncol Rep; 2015 Apr; 33(4):1699-706. PubMed ID: 25647019
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Inactivation of Smad4 accelerates Kras(G12D)-mediated pancreatic neoplasia.
    Kojima K; Vickers SM; Adsay NV; Jhala NC; Kim HG; Schoeb TR; Grizzle WE; Klug CA
    Cancer Res; 2007 Sep; 67(17):8121-30. PubMed ID: 17804724
    [TBL] [Abstract][Full Text] [Related]  

  • 37. FAM84B, amplified in pancreatic ductal adenocarcinoma, promotes tumorigenesis through the Wnt/β-catenin pathway.
    Zhang X; Xu J; Yan R; Zhang Y; Hu Z; Fu H; You Q; Cai Q; Yang D
    Aging (Albany NY); 2020 Apr; 12(8):6808-6822. PubMed ID: 32291380
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Modulation of PKM alternative splicing by PTBP1 promotes gemcitabine resistance in pancreatic cancer cells.
    Calabretta S; Bielli P; Passacantilli I; Pilozzi E; Fendrich V; Capurso G; Fave GD; Sette C
    Oncogene; 2016 Apr; 35(16):2031-9. PubMed ID: 26234680
    [TBL] [Abstract][Full Text] [Related]  

  • 39. HuR modulates gemcitabine efficacy: new perspectives in pancreatic cancer treatment.
    Maréchal R; Van Laethem JL
    Expert Rev Anticancer Ther; 2009 Oct; 9(10):1439-41. PubMed ID: 19828005
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cancer. Breaching the cancer fortress.
    Olson P; Hanahan D
    Science; 2009 Jun; 324(5933):1400-1. PubMed ID: 19520948
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.